Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-cash Items (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Non-cash Items for 11 consecutive years, with $10.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-cash Items rose 21.84% year-over-year to $10.6 million, compared with a TTM value of $10.6 million through Dec 2024, up 21.84%, and an annual FY2024 reading of $10.6 million, up 21.84% over the prior year.
  • Non-cash Items was $10.6 million for Q4 2024 at CytomX Therapeutics, up from $8.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $10.6 million in Q4 2024 and bottomed at $29300.0 in Q4 2022.
  • Average Non-cash Items over 5 years is $5.6 million, with a median of $6.1 million recorded in 2020.
  • The sharpest move saw Non-cash Items tumbled 97.52% in 2022, then soared 29497.31% in 2023.
  • Year by year, Non-cash Items stood at $6.1 million in 2020, then tumbled by 80.77% to $1.2 million in 2021, then crashed by 97.52% to $29300.0 in 2022, then skyrocketed by 29497.31% to $8.7 million in 2023, then grew by 21.84% to $10.6 million in 2024.
  • Business Quant data shows Non-cash Items for CTMX at $10.6 million in Q4 2024, $8.7 million in Q4 2023, and $29300.0 in Q4 2022.